Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety, toxicities, dosage and response
rate for an investigational drug, motexafin gadolinium, administered to patients with chronic
lymphocytic leukemia or small lymphocytic lymphoma. The secondary purpose of this study is to
evaluate the clinical benefit rate, the time it takes for a patient's chronic lymphocytic
leukemia or small lymphocytic lymphoma to worsen, the duration of response and the time
during which patients survive without chronic lymphocytic leukemia or small lymphocytic
lymphoma worsening. Additionally, the patient's response to motexafin gadolinium will be
compared to the response of the patient's cells in a laboratory to motexafin gadolinium.